Eliopoulos G M, Eliopoulos C T
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts.
Eur J Clin Microbiol Infect Dis. 1990 Feb;9(2):118-26. doi: 10.1007/BF01963636.
Because enterococci are typically tolerant of the bactericidal effects of cell wall-active antimicrobial agents, bactericidal therapy has required use of these agents in combination with aminoglycosides. For strains which do not demonstrate high-level aminoglycoside resistance, either streptomycin or gentamicin can be used in combination with penicillin, ampicillin or vancomycin. At some centers, as many as 50% of isolates display high-level gentamicin resistance. A minority of such isolates will not be highly streptomycin-resistant, and the latter drug can be used in combination with a cell wall-active drug. Optimal treatment of serious infections due to strains highly resistant to both streptomycin and gentamicin is unknown. While no agent is predictably bactericidal against such isolates, ampicillin, penicillin or vancomycin alone would be expected to cure some patients. Other drugs or drug combinations do not offer any predictable therapeutic advantages.
由于肠球菌通常对细胞壁活性抗菌药物的杀菌作用具有耐受性,杀菌治疗需要将这些药物与氨基糖苷类联合使用。对于未表现出高水平氨基糖苷类耐药性的菌株,链霉素或庆大霉素可与青霉素、氨苄西林或万古霉素联合使用。在一些中心,多达50%的分离株表现出高水平的庆大霉素耐药性。少数此类分离株对链霉素耐药性不高,后一种药物可与细胞壁活性药物联合使用。对于对链霉素和庆大霉素均高度耐药的菌株所致严重感染的最佳治疗方法尚不清楚。虽然没有药物可预测地对这类分离株具有杀菌作用,但单独使用氨苄西林、青霉素或万古霉素有望治愈一些患者。其他药物或药物组合没有任何可预测的治疗优势。